Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Not yet recruiting 2Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Leukemia, Myeloid, Acute 45Breast Neoplasms 20Myelodysplastic Syndromes 19Prostatic Neoplasms 12Neoplasms 12Leukemia, Myelomonocytic, Chronic 12Carcinoma, Hepatocellular 10Stomach Neoplasms 9Recurrence 9Carcinoma, Non-Small-Cell Lung 8Neoplasm Metastasis 7Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Sarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Ovarian Neoplasms 6Multiple Myeloma 6Lung Neoplasms 6Myeloproliferative Disorders 5Melanoma 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Biphenotypic, Acute 4Leukemia 4Cholangiocarcinoma 4

Interventions

Cisplatin 86Radiotherapy 71Paclitaxel 50Fluorouracil 38Carboplatin 36Drug Therapy 32Neoadjuvant Therapy 23toripalimab 19tislelizumab 18pembrolizumab 17camrelizumab 17Irinotecan 17Esophagectomy 17Surgical Procedures, Operative 16Radiation 16Docetaxel 16sintilimab 15Oxaliplatin 14130-nm albumin-bound paclitaxel 14nimotuzumab 11TP protocol 11S 1 (combination) 11Radiotherapy, Intensity-Modulated 11Cetuximab 11Capecitabine 11Albumin-Bound Paclitaxel 10apatinib 9Leucovorin 9Immune Checkpoint Inhibitors 8nedaplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Esophageal Squamous Cell Carcinoma × Injections × Clear all
NCT07618910 2026-06-01

Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC

Tang-Du Hospital

Phase 2 Not yet recruiting
33 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06356688 2025-08-08

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06508229 2024-07-18

Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC

Harbin Medical University

Phase 2 Not yet recruiting
65 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04506138 2021-12-14

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Zhejiang Cancer Hospital

Phase 1/2 Unknown
46 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04225364 2021-02-02

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Guangzhou Institute of Respiratory Disease

Phase 2 Completed
56 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡